We claim:

1. Compounds of formula (1), and pharmaceutically acceptable salts, solvates, metabolites, prodrugs and solvates thereof,



wherein:

W-Z is -C(=O)-C(-R^3)(H)- or –C(-OR^6)=C(-$R^{3'}$)-;

each R^1 is independently selected from hydrogen, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, (C_3-C_{10}) cycloalkyl, 4- to 10-membered heterocyclic, and C_6-C_{10} aryl, wherein the foregoing R^1 groups, except H, are optionally substituted by 1 to 4 substituents selected from R^4;

R^2 is selected from the group of R^1 substituents, -(CR^8R^9)$_t$(C_3-C_{10} cycloalkyl), -(CR^8R^9)$_t$(C_6-C_{10} aryl), -(CR^8R^9)$_t$(4-10 membered heterocyclic), -(CR^8R^9)$_q$C(O)(CR^8R^9)$_t$(C_6-C_{10} aryl), -(CR^8R^9)$_q$C(O)(CR^8R^9)$_t$(4-10 membered heterocyclic), -(CR^8R^9)$_t$O(CR^8R^9)$_q$(C_6-C_{10} aryl), -(CR^8R^9)$_t$O(CR^8R^9)$_q$(4-10 membered heterocyclic), -(CR^8R^9)$_q$$SO_n$($CR^8R^9$)$_t$($C_6$-$C_{10}$ aryl), and -(CR^8R^9)$_q$$SO_n$($CR^8R^9$)$_t$(4-10 membered heterocyclic), wherein q and t are each independently an integer from 0 to 5, n is an integer from 0 to 2, the alkyl, cycloalkyl, aryl and heterocyclic moieties of said R^2 groups are optionally substituted by 1 to 5 R^4 groups, and with the proviso that R^2 is not H;

R^3 is hydrogen, -OR^6, -SR^6, -NR^6R^7, and the group of R^2 substituents;

$R^{3'}$ is selected from the group of R^3 substituents;

each R^4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_3-C_{10} cycloalkyl, -(CR^8R^9)$_t$N(R^5)$_2$, -(CR^8R^9)$_t$$NR^6$C(O)$R^6$, -($CR^8R^9$)$_t$$OR^6$, --($CR^8R^9$)$_t$C(O)$R^6$, -($CR^8R^9$)$_t$ C(O)OR^6, --(CR^8R^9)$_t$C(O)R^6, -(CR^8R^9)$_t$ NR^6C(O)R^7, -(CR^8R^9)$_t$$NR^6$C(O)$OR^6$ -(CR^8R^9)$_t$$NR^6$C(O)$NR^7$, -($CR^8R^9$)$_t$C(O)$NR^6R^7$, -($CR^8R^9$)$_t$$NR^6R^7$, -($CR^8R^9$)$_t$$NR^6OR^7$, -($CR^8R^9$)$_t$$SO_2NR^6R^7$, --($CR^8R^9$)$_t$$NR^6SO_2R^7$, -($CR^8R^9$)$_t$($C_6$-$C_{10}$ aryl)(wherein t is an integer from 0 to 5), -(CR^8R^9)$_t$(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C_3-C_{10} cycloalkyl, R^6-O-, R^6-SO_n-(CR^8R^9)$_t$- (wherein n is an integer from 0 to 2), and oxo (=O), and wherein the alkyl, aryl, and heterocyclic moieties of said R^4 groups are optionally substituted by 1 to 4 substituents selected from R^5;

each R^5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -OR^8, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 4- to 10-membered heterocyclic, oxo (=O), -$C(O)R^6$, -$C(O)OR^6$, -$OC(O)R^6$, -$NR^6C(O)R^6$, -$NR^6C(O)NR^7$, -$C(O)NR^6R^7$, -NR^6R^7, -NR^6OR^7, -$NR^6SO_2R^7$ and -$SO_2NR^6R^7$, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R^5 groups are optionally substituted by 1 to 3 R^{10};

each R^6 and R^7 is independently selected from H, cyano, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, -$(CR^8R^9)_t$(C_6-C_{10} aryl), and -$(CR^8R^9)_t$(4-10 membered heterocyclic), -$(CR^8R^9)_tC(O)R^8$ wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^6 and R^7 groups are optionally substituted with 1 to 3 halo, cyano, C_3-C_{10} cycloalkyl, -$C(O)OR^8$, -$NR^8C(O)R^9$, -$(CR^8R^9)_tNR^8R^9$, -OR^8, -$NC(O)R^9$, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -$(CR^8R^9)_t$(C_6-C_{10} aryl), and -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5;

each R^8 and R^9 is independently selected from H and C_1-C_4 alkyl; and

each R^{10} is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, -$C(O)OR^6$, –$C(O)O$-R^6, -OR^6, -$C(O)(CR^8R^9)_pC(O)OR^6$, wherein p is an integer from 1 to 5, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and -NR^6R^7.

2. Compounds of formula (2), and pharmaceutically acceptable salts, solvates, metabolites, prodrugs and solvates thereof,



wherein:

W-Z is –C(-OR^6)=C(-$R^{3'}$)-;

R^1 is cyclopentyl;

R^2 is -$(CR^8R^9)_t$(C_6-C_{10} aryl) or -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R^2 groups are optionally substituted by 1 to 5 R^4 groups, and with the proviso that R^2 is not H;

R^3 is hydrogen, -OR^6, -SR^6, -NR^6R^7, and the group of R^2 substituents;

each R^4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -$C(O)R^6$, -$C(O)OR^6$, -$OC(O)R^6$, -$NR^6C(O)R^7$, -$NR^6C(O)NR^7$, -$C(O)NR^6R^7$, -NR^6R^7, -NR^6OR^7, -$SO_2NR^6R^7$, -$NR^6SO_2R^7$,

-$(CR^8R^9)_t(C_6$-C_{10} aryl)(wherein t is an integer from 0 to 5), -$(CR^8R^9)_t$(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C_3-C_{10} cycloalkyl, R^6-O-, R^6-SO_n- (wherein n is an integer from 0 to 2), and oxo (=O), and wherein the alkyl, aryl, and heterocyclic moieties of said R^4 groups are optionally substituted by 1 to 4 substituents selected from R^5;

each R^5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -OR^8, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 4- to 10-membered heterocyclic, oxo (=O), -$C(O)R^6$, -$C(O)OR^6$, -$OC(O)R^6$, -$NR^6C(O)R^6$, -$NR^6C(O)NR^7$, -$C(O)NR^6R^7$, -NR^6R^7, -NR^6OR^7, -$NR^6SO_2R^7$ and -$SO_2NR^6R^7$, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R^5 groups are optionally substituted by 1 to 3 R^{10};

each R^6 and R^7 is independently selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, -$(CR^8R^9)_t(C_6$-C_{10} aryl), and -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^6 and R^7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $(CR^8R^9)_t(C_6$-C_{10} aryl), and -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5;

each R^8 and R^9 is independently selected from H and C_1-C_4 alkyl; and

each R^{10} is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, –$C(O)O$-R^6, -OR^6, -$C(O)(CR^8R^9)pC(O)OR^6$, wherein p is an integer from 1 to 5, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and NR^6R^7.

3. Compounds of formula (3), and pharmaceutically acceptable salts, solvates, prodrugs, and metabolites thereof,



wherein:

W-Z is -C(=O)-C(-R^3)(H)-;

R^1 is cyclopentyl;

R^2 is -$(CR^8R^9)_t(C_6$-C_{10} aryl) or -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R^2 groups are optionally substituted by 1 to 5 R^4 groups, and with the proviso that R^2 is not H;

R^3 is hydrogen;

each R^4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -$C(O)R^6$, -$C(O)OR^6$, -$OC(O)R^6$, -$NR^6C(O)R^7$, -$NR^6C(O)NR^7$, -$C(O)NR^6R^7$, -NR^6R^7, -NR^6OR^7, -$SO_2NR^6R^7$, -$NR^6SO_2R^7$, -$(CR^8R^9)_t$(C_6-C_{10} aryl)(wherein t is an integer from 0 to 5), -$(CR^8R^9)_t$(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C_3-C_{10} cycloalkyl, R^6-O-, R^6-SO_n- (wherein n is an integer from 0 to 2), and oxo (=O), and wherein the alkyl, aryl, and heterocyclic moieties of said R^4 groups are optionally substituted by 1 to 4 substituents selected from R^5;

each R^5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, -OR^8, C_3-C_{10} cycloalkyl, C_6-C_{10} aryl, 4- to 10-membered heterocyclic, oxo (=O), -$C(O)R^6$, -$C(O)OR^6$, -$OC(O)R^6$, -$NR^6C(O)R^6$, -$NR^6C(O)NR^7$, -$C(O)NR^6R^7$, -NR^6R^7, -NR^6OR^7, -$NR^6SO_2R^7$ and -$SO_2NR^6R^7$, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R^5 groups are optionally substituted by 1 to 3 R^{10};

each R^6 and R^7 is independently selected from H, C_1-C_6 alkyl, C_3-C_{10} cycloalkyl, -$(CR^8R^9)_t$(C_6-C_{10} aryl), and -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^6 and R^7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $(CR^8R^9)_t$(C_6-C_{10} aryl), and -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5;

each R^8 and R^9 is independently selected from H and C_1-C_4 alkyl; and

each R^{10} is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, –C(O)O-R^6, -OR^6, -$C(O)(CR^8R^9)pC(O)OR^6$, wherein p is an integer from 1 to 5, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, and NR^6R^7.

4. Compounds of formula (4),



(4)

wherein:

R^1 is cyclopentyl;

R^3 is -$(CR^8R^9)_t$(C_6-C_{10} aryl) or -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R^3 groups are optionally substituted by 1 to 5 R^4 groups;

each R^4 is independently chosen from halo, C_1-C_{10} alkyl, and R^6-O-, and each C_1-C_{10} alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C_1-C_{10} alkyl, and cyano; or

when two adjacent R^4 groups are both C_1-C_{10} alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;

R^6 is hydrogen or C_1-C_{10} alkyl;

R^8 and R^9 are independently chosen from hydrogen and C_1-C_{10} alkyl;

z is an integer from 1 to 5; and

y is an integer from 0 to 5.

5. Compounds according to claim 4, wherein:

R^3 is -$(CR^8R^9)_t$(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the heterocyclic moiety is optionally substituted by 1 to 5 R^4 groups; and

R^8 and R^9 are hydrogen.

6. Compounds according to claim 5, wherein:

R^3 is -$(CH_2)_t$([1,2,4]triazolo[1,5-a]pyrimidinyl), optionally substituted by 1 to 3 R^4 groups;

t is an integer from 1-3; and

y is an integer from 1 to 3.

7. Compounds according to claim 6, wherein:

R^3 is -(CH_2)([1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by 1 to 3 R^4 groups;

each R^4 is independently chosen from halo and C_1-C_{10} alkyl optionally substituted with cyano; or

two adjacent R^4 groups are both C_1-C_{10} alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S;

z is an integer from 2 to 3; and

y is 2.

8. Compounds according to claim 7, wherein:

R^3 is -(CH_2)([1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by 2 R^4 groups; and

each R^4 is independently chosen from halo, -CH_3, and –$C(CH_3)_2CN$.

9. Compounds according to claim 7, wherein two adjacent R^4 groups are both C_1-C_{10} alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S.

10. Compounds according to claim 9, wherein:

R^3 is -(CH_2)([1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by at least one substituent chosen from halo and methyl; and

two adjacent R^4 groups, together with the atoms to which they are attached form a 5-membered ring, wherein in said ring one carbon atom is replaced by O.

11. Compounds of formula (4b),



(4b)

wherein:

R^3 is -(CH_2)([1,2,4]triazolo[1,5-a]pyrimidinyl), substituted by at least one substituent chosen from halo and methyl;

Q is chosen from N, O, and S;

R^{4a}, R^{4b}, and R^{4c} are independently chosen from hydrogen, halo, C_1-C_{10} alkyl, and R^6-O-; and

R^6 is chosen from hydrogen and C_1-C_{10} alkyl.

12. Compounds of formula (5),



(5)

wherein:

R^{4a}, R^{4b}, and R^{4c} are independently chosen from halo and C_1-C_{10} alkyl;

R^{4d}, R^{4e}, and R^{4f} are independently chosen from halo, R^6-O-, and C_1-C_{10} alkyl, wherein said C_1-C_{10} alkyl is optionally substituted with at least one substituent chosen from halo and cyano; and

R^6 is C_1-C_{10} alkyl or hydrogen.

13. Compounds of formula (6),



(6)

wherein R^4 is halo.

14. Compounds according to claim 13, wherein R^4 is chosen from fluorine and chlorine.

15. Compounds of formula (7),



(7)

wherein R^4 is halo.

16. Compounds according to claim 15, wherein R^4 is chosen from fluorine and chlorine.

17. Compounds of formula (8),



(8)

wherein R^4 is halo.

18. Compounds according to claim 17, wherein R^4 is chosen from fluorine and chlorine.

19. Compounds according to claim 6, wherein:

R^3 is -(CH_2)([1,2,4]triazolo[1,5-a]pyrimidinyl), optionally substituted by 1 to 3 R^4 groups;

each R^4 is independently chosen from halo, C_1-C_{10} alkyl, and R^6-O-, and each C_1-C_{10} alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C_1-C_{10} alkyl, and cyano;

z is an integer from 1 to 3; and

y is 2.

20. Compounds according to claim 19, wherein:

R^6 is hydrogen or methyl; and

z is an integer from 2-3.

21. Compounds of formula (9),



(9)

wherein:

R^{4a} is halo or C_1-C_{10} alkyl;

R^{4b}, R^{4c}, and R^{4d} are independently chosen from C_1-C_{10} alkyl and R^6-O-; and

R^6 is hydrogen or methyl.

22. Compounds according to claim 21, wherein:

R^{4a} is halo;

R^{4b} and R^{4c} are each R^6-O-; and

R^{4d} is C_1-C_{10} alkyl.

23. Compounds according to claim 22, wherein:

R^{4a} is fluorine or chlorine;

R^{4b} is $-OCH_3$;

R^{4c} is –OH; and

R^{4d} is $-CH_2CH_3$.

24. Compounds according to claim 23, wherein R^{4a} is chlorine.

25. A compound of formula (10),



(10).

26. A compound of formula (11),



(11).

27. A compound chosen from:

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a-pyrimidin-2-ylmethyl)-6-[2-(3-fluoro-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-cyclopentyl-3-[(5,7-dimethyl [1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-[2-(3-isopropylphenyl)ethyl]dihydro-2*H*-pyran-2,4(3*H*)-dione;

7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2*H*-pyran-3-yl}methyl)-3-methyl-5*H*-[1,3]thiazolo[3,2-*a*]pyrimidin-5-one;

2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;

6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(imidazo[1,2-*a*]pyrimidin-2-ylmethyl)-5,6-dihydro-2*H*-pyran-2-one;

6 *N*-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4,6-dioxotetrahydro-2*H*-pyran-2-yl}ethyl)-2-ethylphenyl]-*N*-methylmethanesulfonamide;

2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1-methyl-1*H*-indol-5-yl)methyl]-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;

6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

3-(5-Chloro-1-isopropyl-1-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

5-{6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-4-methyl-4H-[1,2,4]triazole-3-carboxylic acid methyl ester;

3-(5-Chloro-1-methyl-1H-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;

6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-{[5-(2-furyl)-4-methyl-4*H*-1,2,4-triazol-3-yl]thio}-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5-pyridin-4-yl-4*H*-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2*H*-pyran-2-one;

6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1*H*-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1*H*-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1*H*-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

8-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2*H*-pyran-3-yl}thio)-1,7-dihydro-6*H*-purin-6-one;

6-[2-(5-chlor-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[5-(4-hydroxyphenyl)-4*H*-1,2,4-triazol-3-yl]thio}-5,6-dihydro-2*H*-pyran-2-one;

ethyl 2-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2*H*-pyran-3-yl}thio)[1,2,4]triazolo[1,5-*a*]pyrimidine-6-carboxylate;

6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

2-[4-(2-{5-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;

2-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile;

2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

(+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl-butyronitrile;

1-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;

1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;
6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one;
3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-6-[2-(4-hydroxy-3-propylphenyl)ethyl]-5,6-dihydro-2*H*-pyran-2-one;
6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

N-{2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-ethylphenoxy]ethyl}acetamide;
2-(4-{2-[2-Cyclopentyl-5- 5,7-dimethyl- [1,2,4] triazolo[1,5-a]pyrimidin-2-ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;
2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2-methyl-propionitrile;
2-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-{2-[3-ethyl-4-(2-hydroxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and
pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.

28. A compound chosen from:
2-[4-(2-{5-[(4-chloro-1-methyl-1*H*-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;
2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
(+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;

3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

N-{2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl}ethyl)-2-ethylphenoxy]ethyl}acetamide;

2-(4-{2-[2-Cyclopentyl-5- 5,7-dimethyl- [1,2,4] triazolo[1,5-a]pyrimidin-2-ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;

(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;

(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;

(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;

(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;

(+)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

(-)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;

1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-{2-[3-ethyl-4-(2-hydroxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;

6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;

(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and
the pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.

29. A compound chosen from:
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-*a*]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2*H*-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-*a*]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2*H*-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and
pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.

30. A method of treating Hepatitis C virus in a mammal, comprising administering to said mammal an amount of a compound according to claim 1 that is effective in treating HCV.

31. A method of inhibiting Hepatitis C virus polymerase, comprising contacting said polymerase with a polymerase-inhibiting amount of a compound according to claim 1.

32. A pharmaceutical composition for the treatment of Hepatitis C virus in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating Hepatitis C virus, and a pharmaceutically acceptable carrier.

5